title: Allergic bronchopulmonary aspergillosis--a clinical review.
abstract: Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.
authors.affiliation: Department of Tuberculosis and Chest Diseases, S.N. Medical College, Agra.
authors.forename: Rajesh Kumar
authors.initials: RK
authors.lastname: Gupta
authors.forename: Amol
authors.initials: A
authors.lastname: Chandr
authors.forename: Praveen Bahadur
authors.initials: PB
authors.lastname: Gautam
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D000305:Adrenal Cortex Hormones; D000935:Antifungal Agents; D017964:Itraconazole